课题基金 / 基金详情

Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature

Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature
针对卵巢癌脉管系统的纳米技术平台
批准号:
7983097
负责人:
ANIL K SOOD
金额:
$33.92万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2015-07-31

项目摘要

项目成果

ANIL K SOOD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (See instructions): PROJECT 2 TITLE: Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature PROJECT SUMMARY: Ovarian cancer remains the most deadly malignancy. Targefing angiogenesis is a particulariy attracfive strategy because of the presumed genetic stability of endothelial cells. This is best illustrated by recent successes of anti-angiogenic therapy (e.g., bevacizumab) in patients with solid tumors. However, despite inifial responses, most patients eventually develop tumor progression resulting in their demise. Therefore, new anfi-angiogenesis therapeufic strategies are needed. The overall goal of this project is to develop novel nanoparticle-based strategies to target the tumor vasculature specifically. We propose to ufilize two types of biocompatible therapeufic nanoparticles (chitosan and gold nanoshell nanoparticles) for the delivery of therapeutic payloads (e.g., siRNA) or near-infrared (NIR) laser mediated thermal ablafion. These platforms are supported by Integrated approaches for selective delivery into the tumor vasculature using either rafionally designed mulfi-stage carriers or surface ligands (thioaptamers) selected from screening libraries based on selecfive binding. Using genomic approaches, we have identified novel candidate target genes in ovarian cancer vasculature that will be targeted using RNAi approaches (Aim 1) because many are difficult to inhibit with small molecules or monoclonal anfibodies. In our preliminary findings, we have identified thiophosphate oligonucleotide aptamers (thio-aptamers) that selecfively bind to tumor, but not to normal endothelial cells based on counter selection strategies using freshly isolated endothelial cells from human ovarian cancer or normal ovaries. In Aim 1, we will develop thioaptamertargeted nanoparticles for selecfive delivery of therapeufic siRNA. On the basis of our preliminary findings regarding the critical role of size and shape in vascular localization of nanoparticles, we will pursue rational design of nanoparticles for targeting the tumor vasculature in Aim 2. Gold-based nanoshells offer unique opportunities for thermal ablation using NIR light. In Aim 3, we will develop and characterize novel approaches for thermal ablation of ovarian cancer vasculature using targeted gold nanoshells. All three aims are complementary to each other and findings of this study should allow the design and translafion of new therapeufic approaches for women with ovarian cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
Targeting EGFL6 in Ovarian Cancer
Harnessing the power of exosomes for non-coding RNA delivery
Harnessing the power of exosomes for non-coding RNA delivery
海外基金